UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549
                               ------------------
                                    FORM 6-K

                        REPORT OF FOREIGN PRIVATE ISSUER
                        PURSUANT TO RULE 13a-16 OR 15d-16
                    UNDER THE SECURITIES EXCHANGE ACT OF 1934
                               ------------------
                           For the month of July 2004

                        Commission File Number: 001-31368

                                SANOFI-SYNTHELABO
                 (Translation of registrant's name into English)

                   174, avenue de France, 75013 Paris, FRANCE
                    (Address of principal executive offices)

         Indicate by check mark whether the registrant files or will file annual
reports under cover Form 20-F or Form 40-F.

                           Form 20-F   [X]              Form 40-F   [ ]

         Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(1):_____

         Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(7):_____

         Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the information to
the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.

                           Yes   [ ]                    No   [X]

         If "Yes" marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2(b):  82-________


         This Report on Form 6-K shall be deemed to be incorporated by reference
into Sanofi-Synthelabo's Registration Statement on Form F-4 (Registration No.
333-112314), as post-effectively amended and declared effective on May 13, 2004
by the United States Securities Exchange Commission, and the related prospectus,
dated April 9, 2004, and the prospectus supplement, dated May 27, 2004, each
filed pursuant to Rule 424(b) under the United States Securities Act of 1933, as
amended, and shall be part thereof from the date on which this Report is filed,
to the extent not superseded by documents or reports subsequently filed or
furnished.



                                                        [SANOFI-SYNTHELABO LOGO]


[GRAPHIC OMITTED] Investor Relations


                                                          Paris, July 13th, 2004


Dear Madam, Dear Sir,

On the occasion of the 2004 HALF-YEAR SALES publication, a CONFERENCE CALL for
financial analysts, institutional investors and journalists will be held on
WEDNESDAY, JULY 21ST, 2004 AT 2.00 P.M. (Paris time). This conference will be
held in English.

In order to participate in the conference call, the following numbers are to be
dialed 10 minutes before it starts :

   France :              00 33 (0) 1 70 70 81 78          code :  211199
   United Kingdom :      00 44 (0) 207 019 95 04          code :  211199
   USA :                 00 1 718 354 11 52               code :  211199


A live audio webcast of this conference will be available at our internet site
(www.sanofi-synthelabo.com).

No recorded version will be archived for this conference.

Yours sincerely,



Philippe Goupit


INVESTOR RELATIONS DEPARTMENT
Philippe Goupit         Director of Investor Relations
Arnaud Delepine         Investor Relations Europe
Sanjay Gupta            Investor Relations US
Anne d'Halluin-Sulzer   Investor Relations

CONTACTS
E-mail: investor-relations@sanofi-synthelabo.com
Europe                          US
Tel: + 33 1 53 77 45 45         Tel.: + 1 212 551 40 18
Fax: + 33 1 53 77 42 96         Fax : + 1 646 487 40 18







                                   SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.


Dated: July 15, 2004                       SANOFI-SYNTHELABO


                                           By:     /s/ Marie-Helene Laimay
                                              ----------------------------------
                                              Name:    Marie-Helene Laimay
                                              Title:   Senior Vice President and
                                                       Chief Financial Officer